Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 10697 - 10704 of 12027 results

What Do the Proposed Changes to Medicare Parts C and D Mean For Your Business?
January 22, 2014| Blog| Viewpoint

MA Appeals Court Narrows but Otherwise Keeps Intact Individual Liability Under the Wage Act
January 21, 2014| Blog| Viewpoint

The Affordable Care Act—Countdown to Compliance for Employers, Week 49: Waiting for the Final Code Section 4980H Regulations
January 21, 2014| Blog| Viewpoint

Why A-Rod Faces Long Odds in His Attempt to Overturn the Grievance Arbitration Award
January 21, 2014| Blog| Viewpoint

Look North, Marketers - Canadian Anti-Spam Law is Coming
January 21, 2014| Blog| Viewpoint

ML Strategies Posts Weekly Health Care Reform Update on January 21, 2014
January 21, 2014| Blog| Viewpoint

CMS Proposes Major Changes to Medicare Parts C and D
January 21, 2014| Advisory| Viewpoint

New York City Looks to Expand its Paid Sick Leave Law Before it Takes Effect in April 2014
January 20, 2014| Blog| Viewpoint
News & Press Releases
San Francisco Business Times featured Mintz’s new office lease in San Francisco at 525 Market St. The firm will be increasing its footprint in downtown by 50% to 29,000 square feet on a whole single floor with the new space.
Mintz advised the underwriters in connection with a $230 million public offering by Cogent Biosciences, Inc. of 25,555,556 shares of common stock, which includes 3,333,333 shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering were approximately $230 million, including proceeds from the exercise in full by the underwriters of the option to purchase additional shares, before deducting underwriting discounts and commissions and other offering expenses.
Mintz advised the underwriters in connection with a $200 million public offering by Soleno Therapeutics, Inc. of 2,352,941 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds to Soleno from the offering were approximately $200 million before deducting underwriting discounts and commissions and other offering expenses. In addition, Soleno granted the underwriters a 30-day option to purchase up to an additional 352,941 shares of its common stock at the public offering price.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts

Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|

Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
